Stock LCTX LINEAGE CELL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Lineage Cell Therapeutics, Inc.

Equities

LCTX

US53566P1093

Market Closed - Nyse
Other stock markets
 21:00:00 15/05/2024 BST 		5-day change 1st Jan Change
1.09 USD +4.81% Intraday chart for Lineage Cell Therapeutics, Inc. -6.03% 0.00%
05-09 Transcript : Lineage Cell Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
05-09 Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q1 Revenue $1.4M, vs. Street Est of $1.36M MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lineage Cell Therapeutics : Immediate Report
PU
Lineage Cell: Q1 Earnings Snapshot
AQ
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
BU
LINEAGE CELL - OPREGEN PHASE 1/2A CLINICAL STUDY 24-MONTH VISUAL ACUITY RESULTS FEATURED AT 2024 RETINAL CELL AND GENE THERAPY INNOVATION SUMMIT
AQ
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
BU
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
BU
LINEAGE RECEIVES GRANT FROM CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE
AQ
Lineage Cell Therapeutics : Immediate Report
PU
Lineage Cell Therapeutics : Additional proxy soliciting materials - definitive
PU
Lineage Cell Therapeutics : NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 11, 2024, PROXY
PU
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
BU
Lineage Announces Changes to Board of Directors
BU
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
BU
Lineage Cell Therapeutics : Immediate Report
PU
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
BU
LINEAGE CELL THERAPEUTICS, INC. - RG6501 PHASE 1/2A CLINICAL STUDY 24 MONTH RESULTS TO BE FEATURED AT 2024 RETINAL CELL AND GENE THERAPY INNOVATION SUMMIT
AQ
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
BU
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
BU
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Samuel George A. III
PU
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP- Cukkey Brian M
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LCTX Stock
  4. News Lineage Cell Therapeutics, Inc.
  5. Press Releases